Skip to main content
[Preprint]. 2023 Apr 3:rs.3.rs-2709282. [Version 1] doi: 10.21203/rs.3.rs-2709282/v1

Figure 9. The effects of Vactosertib with ICB (α-PD-1/ α-PD-L1 mAbs) in pOS in vivo.

Figure 9.

A) BALB/c mice were inoculated with 1×106 K7M2-Luc (i.v.) on Day 0, and then treated with Vactosertib (50 mg/kg , p.o. 5 days/week) with/without anti-PD-1 antibody or anti-PDL-1 antibody (100 ug/mice/week, i.p.) starting on day 21 (3 weeks). Bioluminescence image intensity (BLI) was measured once a week. N=9–13/group, *** p<0.001 using a two-way ANOVA B) BLI at 11 weeks after tumor injections. n=10–13, Control is the lung sample of mice without tumor injection. ***p<0.001 using an unpaired two-tailed t-test C) survival rate of isotype, Vactosertib, anti ICB antibodies after K7M2-luc injection to BALB/c mice (n=25). D) FACS analysis of NK-cell (CD49b+CD3−) and myeloid (F4/80+CD11b+PD-L1+, F4/80+CD11b+Arg1+) cells in OS TME. N=513/group, *p<0.05, ** p<0.01, *** p<0.001 using a one-way ANOVA analysis followed by post-hoc 889 Bonferroni’s multiple comparison tests.